AlloDx at the 2019 China Organ Transplantation Conference
On August 2, 2019, the 2019 China Organ Transplantation Conference and the 6th China Organ Transplant Physicians Annual Conference were grandly held at the Baiyun International Conference in Guangzhou, Guangdong Province. The theme of this conference was "Extensive research, vigorous research and vigorous development". Nearly 300 experts and scholars at home and abroad gave wonderful academic reports and shared cutting-edge scientific knowledge and clinical experience, attracting people from all over the country.
On August 2, 2019, the 2019 China Organ Transplantation Conference and the 6th China Organ Transplant Physicians Annual Conference were grandly held at the Baiyun International Conference in Guangzhou, Guangdong Province. With the theme of "Extensive research and vigorous development", nearly 300 experts and scholars at home and abroad gave wonderful academic reports and shared cutting-edge scientific knowledge and clinical experience. It attracted more than 1,000 colleagues in the transplant field from all over the country to attend the conference, presenting a wonderful academic feast to the participants.
AlloDx appeared at this conference with its independently developed "AoYin series of non-invasive testing products". This series of products pioneered non-invasive testing for organ transplantation in China, attracting participating experts to the booth for exchanges.
The AoYin series of products is a comprehensive set of non-invasive testing solutions developed for the solid organ transplant population. It can detect subclinical rejection early, screen for pathogenic microbial infections, differentially diagnose polyomavirus-related nephropathy, and early screening for GVHD. It can assist clinicians in carrying out precise treatment and help transplant recipients obtain earlier diagnostic monitoring.
About AlloDx
AlloDx (AlloDx) was founded in 2016 and focuses on precision medicine in the field of organ transplantation. The company is headquartered in Pujiang High-Tech Park, Shanghai, and has branches and testing laboratories in Suzhou, Guangzhou and other places. As a pioneer in the domestic post-transplantation liquid biopsy market, the company is based on its omics detection platform, bioinformatics analysis platform and data deep learning platform, and by integrating the Internet medical platform "AlloDx Health+", it hopes to create a new medical service model after transplantation and help improve the long-term survival of patients' grafts.
RECOMMENDRecommended Reading
Oin series products:https://www.allograftdx.com/product
Some original figures, videos and downloadable materials are provided in Chinese.